On January 13, 2026, Novavax CEO John Jacobs opened the company’s presentation at the 44th Annual J.P. Morgan Healthcare Conference, joined by senior biotech analysts Anupam Rama, Priyanka Grover, Joyce Tso and Rati Pinhe. Jacobs reiterated the critical importance of reviewing the company’s SEC filings and slide-deck disclaimers, emphasizing the company’s commitment to transparency around risk factors. He presented Novavax’s refined vision statement—crafted to guide the organization’s 1,200 global employees—and underscored the firm’s dedication to leveraging protein-based vaccine technology to address both emerging and endemic infectious diseases. Jacobs noted that Novavax has invested over $350 million in advanced manufacturing capacity to support late-stage clinical assets, signaling readiness to scale upon regulatory approval.